These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 28802986)

  • 1. Research digest: more cardiovascular outcome trials in diabetes.
    Sattar N; Preiss D
    Lancet Diabetes Endocrinol; 2017 Sep; 5(9):687. PubMed ID: 28802986
    [No Abstract]   [Full Text] [Related]  

  • 2. SGLT2 inhibitors: hypotheses on the mechanism of cardiovascular protection.
    Bell RM; Yellon DM
    Lancet Diabetes Endocrinol; 2018 Jun; 6(6):435-437. PubMed ID: 29030201
    [No Abstract]   [Full Text] [Related]  

  • 3. Glucose-lowering drugs: balancing risks and benefits.
    The Lancet Diabetes Endocrinology
    Lancet Diabetes Endocrinol; 2017 Sep; 5(9):669. PubMed ID: 28802987
    [No Abstract]   [Full Text] [Related]  

  • 4. ORIGIN trial shows safety and efficacy of insulin glargine: no adverse cardiovascular outcomes after a 6.2-year follow up of early insulin use.
    Lombard L; Distiller L; Aalbers J
    Cardiovasc J Afr; 2012 Jul; 23(6):357-8. PubMed ID: 23091824
    [No Abstract]   [Full Text] [Related]  

  • 5. Results from Cardiovascular Outcome Trials in Diabetes.
    Muñoz Torres M; Muñoz Garach A
    Endocrinol Nutr; 2016; 63(7):317-9. PubMed ID: 27324936
    [No Abstract]   [Full Text] [Related]  

  • 6. [Early insulin therapy in type 2 diabetes?].
    Birkeland KI
    Tidsskr Nor Laegeforen; 2012 Oct; 132(19):2151-2. PubMed ID: 23076480
    [No Abstract]   [Full Text] [Related]  

  • 7. Canagliflozin and cardiovascular and renal events in type 2 diabetes.
    Guthrie R
    Postgrad Med; 2018 Mar; 130(2):149-153. PubMed ID: 29297732
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Basal insulin and cardiovascular and other outcomes.
    Leow MK
    N Engl J Med; 2012 Nov; 367(18):1763; author reply 1763-4. PubMed ID: 23113497
    [No Abstract]   [Full Text] [Related]  

  • 9. Basal insulin and cardiovascular and other outcomes.
    Ceriello A
    N Engl J Med; 2012 Nov; 367(18):1762-3; author reply 1763-4. PubMed ID: 23113496
    [No Abstract]   [Full Text] [Related]  

  • 10. Basal insulin and cardiovascular and other outcomes.
    Schernthaner G; Currie CJ
    N Engl J Med; 2012 Nov; 367(18):1762; author reply 1763-4. PubMed ID: 23113495
    [No Abstract]   [Full Text] [Related]  

  • 11. Basal insulin and cardiovascular and other outcomes.
    Vigneri R; Vigneri P; Frittitta L
    N Engl J Med; 2012 Nov; 367(18):1761-2; author reply 1763-4. PubMed ID: 23113494
    [No Abstract]   [Full Text] [Related]  

  • 12. n-3 fatty acids and cardiovascular outcomes in dysglycemia.
    Hurtado-Torres GF; Sandoval-Munro RL
    N Engl J Med; 2012 Nov; 367(18):1760-1; author reply 1761. PubMed ID: 23113492
    [No Abstract]   [Full Text] [Related]  

  • 13. n-3 fatty acids and cardiovascular outcomes in dysglycemia.
    Levy Y
    N Engl J Med; 2012 Nov; 367(18):1760; author reply 1761. PubMed ID: 23113491
    [No Abstract]   [Full Text] [Related]  

  • 14. The diabetologist/cardiologist debate: a meeting of the minds.
    Mohamed F; Aalbers J
    Cardiovasc J Afr; 2012 Mar; 23(2):115-7. PubMed ID: 22447480
    [No Abstract]   [Full Text] [Related]  

  • 15. N-3 fatty acids did not reduce major cardiovascular events in patients with dysglycaemia.
    Kromhout D
    Evid Based Med; 2013 Aug; 18(4):e34. PubMed ID: 23173155
    [No Abstract]   [Full Text] [Related]  

  • 16. SGLT2 inhibitors: new reports.
    Med Lett Drugs Ther; 2015 Oct; 57(1479):139-40. PubMed ID: 26445203
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of canagliflozin in patients with type 2 diabetes based on history of cardiovascular disease or cardiovascular risk factors: a post hoc analysis of pooled data.
    Davies MJ; Merton K; Vijapurkar U; Yee J; Qiu R
    Cardiovasc Diabetol; 2017 Mar; 16(1):40. PubMed ID: 28327140
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Early insulin therapy reduces cardiovascular risk].
    Med Monatsschr Pharm; 2007 Apr; 30(4):160-1. PubMed ID: 17484451
    [No Abstract]   [Full Text] [Related]  

  • 19. Canagliflozin: a new option for managing diabetes.
    Livingston M; Clements JN
    JAAPA; 2014 Sep; 27(9):47-50. PubMed ID: 25148443
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [What has the largest study in the history of diabetology brought us?].
    Rusavý Z; Lacigová S; Kvapil M
    Vnitr Lek; 2013 Mar; 59(3):160-4. PubMed ID: 23713181
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.